美国生物技术公司Sarepta Therapeutics(SRPT)周二夜盘股价大跌5.06%，引发市场广泛关注。这一大跌主要源于公司一款关键药物的临床试验结果令人失望。
根据公司最新公布的消息，Sarepta Therapeutics一款已获批准的针对杜氏肌营养不良症(DMD)的靶向基因疗法药物在确证性试验中未能达到主要目标。这一结果给投资者带来沉重打击，因为该药物被视为公司未来增长的重要驱动力。
杜氏肌营养不良症是一种罕见的遗传性肌肉退化疾病，目前尚无根治方法。Sarepta的这款药物曾被寄予厚望，有望为患者带来新的治疗选择。然而，这次试验失败不仅可能影响药物的进一步开发和商业化前景，还可能对公司的整体研发战略和财务状况产生连锁反应。市场对这一负面消息反应强烈，导致公司股价在夜盘交易中大幅下挫。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.